Novartis Cosentyx receives FDA approval for paediatric plaque psoriasis releases JIA data

Compileriver

According to foreign media reports on June 2, the FDA has approved Novartis’ blockbuster product Cosentyx for use in pediatric patients 6 years and older with moderate to severe plaque psoriasis

Cosentyx's new approval for children with psoriasis is supported by data from two other phase III trials that evaluated the treatment of children between the ages of 6 and 18

In this study, participants using Cosentyx at week 12 significantly reduced the severity of the disease compared to placebo

Just one day after Novartis announced that Cosentyx received new FDA approval, the company also released positive phase III data for the treatment of juvenile idiopathic arthritis (JIA)

The study showed that treatment with Cosentyx caused a significant delay in the onset time of children with two different types of JIA compared with placebo

Although Cosentyx has brought huge profits to Novartis, Cosentyx has consistently ranked first in its new drug revenue with sales of US$1.

Reference source:

1.

2.